Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
26 hedge funds and large institutions have $5.6M invested in Hepion Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
155% more capital invested
Capital invested by funds: $2.2M → $5.6M (+$3.4M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.6K |
| 2 |
Renaissance Technologies
New York
|
+$28.1K |
| 3 |
VF
Virtu Financial
New York
|
+$24.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$10.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$34K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$15.5K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$8.13K |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$7.39K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$5.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $410 | – | – | – |
|
27
Barclays
London,
United Kingdom
| $240 | – | – | – |
|
|
S
28
SignatureFD
Atlanta,
Georgia
| $2 | – | – | – |
|
|
AF
29
Allworth Financial
Folsom,
California
| $1 | – | – | – |
|
|
HIA
30
Harbor Investment Advisory
Lutherville,
Maryland
| $1 | – | – | – |
|
|
RJFSA
31
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$5.48K | -18 | Closed |
|
|
BFEC
32
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$739 | -1 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$54 | – | – |
|
|
IA
34
IFP Advisors
Tampa,
Florida
| – | -$1K | – | – |
|
HEPA Hedge Fund Activity: Q1 2023 in Review
26 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2023, worth a combined $5.6M — up 155% from $2.2M a quarter earlier.
Fund positioning in HEPA was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $43.6K. The largest seller was Envestnet Asset Management, cutting an estimated $34K.
- 26 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $5.6M of Hepion Pharmaceuticals stock for Q1 2023, up 155% quarter-over-quarter.
- 2 funds opened new Hepion Pharmaceuticals positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2023 was Susquehanna International Group, an estimated $43.6K added.
- The largest Hepion Pharmaceuticals seller in Q1 2023 was Envestnet Asset Management, an estimated $34K sold.
Based on aggregated 13F filings for Q1 2023.